Swift S - Search Results

1

Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head-to-head placebo-controlled trial.

Herschorn S, Swift S, Guan Z, Carlsson M, Morrow JD, Brodsky M, Gong J. Herschorn S, et al. Among authors: swift s. BJU Int. 2010 Jan;105(1):58-66. doi: 10.1111/j.1464-410X.2009.09086.x. BJU Int. 2010. PMID: 20132103 Clinical Trial.

2

Diary and patient-reported outcomes in patients with severe overactive bladder switching from tolterodine extended release 4 mg/day to solifenacin treatment: An open-label, flexible-dosing, multicentre study.

Swift SE, Siami P, Forero-Schwanhaeuser S. Swift SE, et al. Clin Drug Investig. 2009;29(5):305-16. doi: 10.2165/00044011-200929050-00003. Clin Drug Investig. 2009. PMID: 19366272 Clinical Trial.

3

Efficacy of fesoterodine compared with extended-release tolterodine in men and women with overactive bladder.

Ginsberg D, Schneider T, Kelleher C, Van Kerrebroeck P, Swift S, Creanga D, Martire DL. Ginsberg D, et al. Among authors: swift s. BJU Int. 2013 Aug;112(3):373-85. doi: 10.1111/bju.12174. BJU Int. 2013. PMID: 23826844 Clinical Trial.

4

A new once-daily formulation of tolterodine provides superior efficacy and is well tolerated in women with overactive bladder.

Swift S, Garely A, Dimpfl T, Payne C; Tolterodine Study Group. Swift S, et al. Int Urogynecol J Pelvic Floor Dysfunct. 2003 Feb;14(1):50-4; discussion 54-5. doi: 10.1007/s00192-002-1009-0. Int Urogynecol J Pelvic Floor Dysfunct. 2003. PMID: 12601517 Clinical Trial.

5

Transcutaneous posterior tibial nerve stimulation versus extended release oxybutynin in overactive bladder patients. A prospective randomized trial.

Manríquez V, Guzmán R, Naser M, Aguilera A, Narvaez S, Castro A, Swift S, Digesu GA. Manríquez V, et al. Among authors: swift s. Eur J Obstet Gynecol Reprod Biol. 2016 Jan;196:6-10. doi: 10.1016/j.ejogrb.2015.09.020. Epub 2015 Oct 20. Eur J Obstet Gynecol Reprod Biol. 2016. PMID: 26645117 Clinical Trial.

6

Efficacy of antimuscarinic therapy for overactive bladder with varying degrees of incontinence severity.

Landis JR, Kaplan S, Swift S, Versi E. Landis JR, et al. Among authors: swift s. J Urol. 2004 Feb;171(2 Pt 1):752-6. doi: 10.1097/01.ju.0000103540.71683.e5. J Urol. 2004. PMID: 14713803 Clinical Trial.

7

Treatment outcomes of overactive bladder with combined therapies of botulinum toxin injections and oral agents.

Woll A, Edenfield A, Locke M, Swift S. Woll A, et al. Among authors: swift s. Int Urogynecol J. 2021 Oct;32(10):2803-2806. doi: 10.1007/s00192-021-04676-3. Epub 2021 Feb 23. Int Urogynecol J. 2021. PMID: 33620537

8

Pelvic floor electrical stimulation in the treatment of genuine stress incontinence: a multicenter, placebo-controlled trial.

Sand PK, Richardson DA, Staskin DR, Swift SE, Appell RA, Whitmore KE, Ostergard DR. Sand PK, et al. Among authors: swift se. Am J Obstet Gynecol. 1995 Jul;173(1):72-9. doi: 10.1016/0002-9378(95)90172-8. Am J Obstet Gynecol. 1995. PMID: 7631730 Free article. Clinical Trial.

9

Solifenacin is effective for the treatment of OAB dry patients: a pooled analysis.

Abrams P, Swift S. Abrams P, et al. Among authors: swift s. Eur Urol. 2005 Sep;48(3):483-7. doi: 10.1016/j.eururo.2005.06.007. Eur Urol. 2005. PMID: 16005564

10

Intrasubject variability of the pressure-transmission ratio in patients with genuine stress incontinence.

Swift SE, Rust PF, Ostergard DR. Swift SE, et al. Int Urogynecol J Pelvic Floor Dysfunct. 1996;7(6):312-6. doi: 10.1007/BF01901105. Int Urogynecol J Pelvic Floor Dysfunct. 1996. PMID: 9203478

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

683 results

Search Page

Filters